Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Angela Duffy
  • March 18, 2020
  • Articles

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Senior Director Angela Duffy was recently interviewed by PME Magazine about the steps needed to close the gap between rhetoric and reality in patient-centricity, and why it’s vital to include patients in every step.

“When I grew up in the industry, things were pretty well set in terms of how pharmaceutical companies engaged with patients - which is to say that you didn’t engage all that much.” Ron Cohen’s reflection on ‘Pharma Past’ will be familiar to many who worked in the industry in the era before patient-centricity became the biggest of buzzwords. Speaking to McKinsey in 2016, the biotech CEO argued that a new generation of engagement was dawning. 

read more »

  • Posted by Sue Rees
  • July 10, 2019
  • Articles

New hopes for Mexico

New hopes for Mexico

What will be the future of healthcare under the country's new administration?

In December 2018 the new Mexican President, Andres Manuel Lopez Obrador came into office after a landslide victory of over 65% of the votes (more than 30 billion voters). López Obrador was a former Mexico City mayor and has been a major political figure for over twenty years. Widely regarded as both a populist and nationalist, his ideology is to end poverty and improve the lives of his people by fighting corruption and increasing austerity within the government. 

read more »

  • Posted by Pei Li Teh
  • June 11, 2019
  • Articles

Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?

Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?

China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets

It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics. 

read more »

  • Posted by Helen Parfitt, Mariel Metcalfe and Mark Hollis
  • March 22, 2019
  • Webinars

Navigating new frontiers: Ways to find space in the future RA market

Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).

read more »

  • Posted by Anthony Greenwood
  • October 30, 2018
  • Blogs

Could you nudge your brand to success using behavioural economic theory?

Could you nudge your brand to success using behavioural economic theory?

With behavioural economics theory becoming more widely adopted, especially within the market research sector, terms such as ‘nudging’ have started to enter our vocabulary. Director Anthony Greenwood discusses what ‘nudging’ means for market research and the role it could play in marketing pharma and med-tech brands.

read more »